New 14-mm diameter Niti-S biliary uncovered metal stent for unresectable distal biliary malignant obstruction  

作　　者：Masataka Kikuyama Naofumi Shirane Shinya Kawaguchi Shuzou Terada Tsuyoshi Mukai Ken Sugimoto 

机构地区：[1]Departmentof Gastroenterology, Komagome Metropolitan Cancer and Infectious Diseases Center Komagome Hospital [2]Department of Gastroenterology, Shizuoka General Hospital [3]Department of Gastroenterology, Gifu Municipal Hospital [4]Department of Gastroenterology, Hamamatsu University School of Medicine

出　　处：《World Journal of Gastrointestinal Endoscopy》2018年第1期16-22,共7页世界胃肠内镜杂志（英文版）（电子版）

摘　　要：AIM To investigate whether an uncovered self-expandable metal stent(UCSEMS) with a large diameter could prevent recurrent biliary obstruction(RBO).METHODS Thirty-eight patients with malignant biliary obstruction underwent treatment with an UCSEMS with a 14-mm diameter(Niti-S 14). Retrospectively, we evaluated technical and functional success rate, RBO rate, time to RBO, survival time, and adverse events in these patients.RESULTS Stent placement success and functional success were achieved in all patients. Two patients(5.3%) had RBO due to tumor ingrowth or overgrowth. The median time to RBO was 190(range, 164-215) d. The median survival time was 120(range, 18-502) d. The 6-mo non-RBO rate was 91%. Other adverse events other than RBO occurred as follows: Acute cholecystitis, post-ERCP pancreatitis, hemobilia, and fever without exacerbation of liver injury, and liver abscess in 4(10.3%), 3(7.9%), 2(5.3%), 1(2.6%), and 1(2.6%), respectively. Migration of the stents was not observed.CONCLUSION Niti-S 14 is considered to be a preferable metal stent because of a low rate of RBO with no migration.AIM To investigate whether an uncovered self-expandable metal stent(UCSEMS) with a large diameter could prevent recurrent biliary obstruction(RBO).METHODS Thirty-eight patients with malignant biliary obstruction underwent treatment with an UCSEMS with a 14-mm diameter(Niti-S 14). Retrospectively, we evaluated technical and functional success rate, RBO rate, time to RBO, survival time, and adverse events in these patients.RESULTS Stent placement success and functional success were achieved in all patients. Two patients(5.3%) had RBO due to tumor ingrowth or overgrowth. The median time to RBO was 190(range, 164-215) d. The median survival time was 120(range, 18-502) d. The 6-mo non-RBO rate was 91%. Other adverse events other than RBO occurred as follows: Acute cholecystitis, post-ERCP pancreatitis, hemobilia, and fever without exacerbation of liver injury, and liver abscess in 4(10.3%), 3(7.9%), 2(5.3%), 1(2.6%), and 1(2.6%), respectively. Migration of the stents was not observed.CONCLUSION Niti-S 14 is considered to be a preferable metal stent because of a low rate of RBO with no migration.

关 键 词：Metal stent Malignant BILIARY OBSTRUCTION Pancreatic CANCER Migration Pancreatitis Bile duct CANCER OVERGROWTH Recurrent BILIARY OBSTRUCTION INGROWTH Adverse event 

分 类 号：R[医药卫生]